Nanoform (NANOFH.HE)

Executive Summary

Nanoform is a nanotechnology company headquartered in Helsinki, Finland, specializing in drug particle engineering via its proprietary Controlled Expansion of Supercritical Solutions (CESS) platform. The CESS technology enables the nanonization of drug particles, enhancing bioavailability and enabling novel formulations for poorly soluble drugs. Nanoform serves the international pharmaceutical industry by providing expert services and partnership opportunities for drug development. As a private company with operations spanning from preclinical to commercial stages, Nanoform is positioned to capture value from the growing demand for solubility enhancement technologies. The company's laser focus on nanoparticle engineering, combined with a strong intellectual property portfolio, underpins its potential to become a key enabler for next-generation therapies. However, revenue generation remains tied to partnership milestones and service fees, and the path to profitability is contingent upon scaling commercial agreements. With a lean operational model and a presence in the attractive drug delivery market, Nanoform represents a high-risk, high-reward opportunity in the nanotechnology space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major pharmaceutical partnership utilizing CESS technology55% success
• Q4 2026Publication of positive preclinical data for a lead partnered program60% success
• Q1 2027Upscaling of manufacturing capacity or securing grant funding for expansion70% success